Pepti Review: $99 Semaglutide, One Unresolved Flag

Pepti (hellopepti.com) sells 68 prescription SKUs through a single-page app, and injectable semaglutide is $99 a month. That is the cheapest verified GLP-1 rung of the seven providers we screened in August 2026, and it is a genuinely notable number. It also comes attached to a contradiction sitting in the company's own production data that we could not resolve, and you should read both halves of this before you decide.

What the site charges

Injectable semaglutide is $99 a month and injectable tirzepatide is $199 a month, on a subscription you can cancel at any time with no minimum term and a pause of up to 90 days.¹ Buy either as a one-time order instead and the price is the subscription rate times 1.25 — $124 and $249. The subscription price is flat at every titration dose, which is the headline the site leads with.

Beyond the injectables: oral semaglutide $249, oral tirzepatide $399, GLP-1 oral drops $239, GLP-1/GIP oral drops $349, and two longevity microdose SKUs at $149 and $229.¹ The wider shelf is unusually deep for a GLP-1 seller — BPC-157 $209, a BPC-157/TB-500 stack $289, KLOW $299, KPV $229, NAD+ at $179 injectable, $219 nasal and $159 capsule, sermorelin and tesamorelin $189 each, CJC-1295/ipamorelin $239, DSIP for sleep $189, PT-141 $199 injectable and $189 nasal, plus at-home blood panels at $199 one-off or $169 on a plan.

The flag: a second price ladder nobody can buy

Pepti's server payload for its semaglutide and tirzepatide pages carries a per-dose price array — semaglutide $299 at 0.25 mg, $349 at 0.5, $399 at 1.0 and $449 at 2.4; tirzepatide $349 at 2.5 mg, $399 at 5, $449 at 7.5 and $549 at 15. No component on the site renders it. Nothing in the shipped code reads it. Meanwhile the cost page says, in as many words, that every dose is one flat monthly price of $99.

We filed $99 and $199 because that is what the page shows, what the catalog object carries and what the cost page and three cross-sell surfaces all repeat. But a dead ladder averaging roughly three times the headline is not nothing, and the obvious way to settle it — walking the intake to a real checkout — was closed to us, because the checkout endpoint answers only to POST. So this is unresolved, and we are not going to pretend otherwise. If you are considering Pepti, screenshot the price at the moment you check out and compare it with the price you were quoted at 0.25 mg once your dose steps up. That is a five-second check that answers a question we could not.

Two more places the site disagrees with itself

States. Four separate surfaces — the shipping page, the state-availability page, the providers page and the homepage title — publish the same list of 36 states. The Terms of Service say the service is available in 50.² Thirty-six is corroborated four ways and it is the number we treat as operative, so check the list before you start rather than trusting the terms.

When you get charged. The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before a licensed provider reviews your intake.³ Same site, opposite claims. The refund policy is the operative document, so assume the card is charged first: a provider denial gets you a full refund in five to ten business days, and nothing is refundable once medication ships.

Real prescribers, no NPIs, no pharmacy

Pepti names its clinicians and gives them full bios — Dr. Gene Lee, MD, medical director, family medicine, licensed across 26 named states; Dr. Laeeq Butt, MD, MBA, chief medical officer, internal medicine, 15 named states. That is more than most of this cohort does. But neither bio publishes an NPI, so neither can be checked against the national registry, and the pharmacy is only ever described as an independent FDA-registered 503A or 503B compounder — never named. The legal entity is pepti LLC at a Newark, Delaware address that is a registered-agent suite rather than an operating site.

We ran the FDA warning-letter index against the company, its entity and the peptide-seller neighborhood it sits in. Nothing matched Pepti in the company column, and the same pass returned a known 2026 letter for an unrelated control seller, so the zero is a reading rather than a silence.⁴

One thing we will not recommend

Pepti's catalog includes retatrutide, melanotan II and IGF-1 LR3. Retatrutide has no FDA approval in any form anywhere. We do not surface any of the three as an option on this site, on any ranking, at any price, and a provider selling them is not thereby disqualified — but you should know they are on the shelf before you go looking around it.

Who this is a match for

Budget Fit is your top slider and you live in one of the 36 published states. You want the same price at 0.25 mg and at 2.4 mg rather than a ladder that climbs as your dose does. You are comfortable pausing rather than canceling, and you want a deep non-GLP-1 shelf on the same account. On price alone nothing else we checked this month gets near $99 — see semaglutide cost without insurance for where that sits against the rest of the market.

Who should walk away

You want certainty about what you will be charged in month six, because that is the one thing this file cannot give you. You live in one of the 14 states not on the published list. You need a prescriber you can verify in the national registry or a pharmacy you can name — The Edit gives you both and charges $209 for it, which is what that premium buys. And if you are choosing on support rather than price, read how to choose a GLP-1 provider before you let a headline number make the decision.